Cargando…

New Thiazolyl-Pyrazoline Derivatives as Potential Dual EGFR/HER2 Inhibitors: Design, Synthesis, Anticancer Activity Evaluation and In Silico Study

A new series of thiazolyl-pyrazoline derivatives (4a–d, 5a–d 6a, b, 7a–d, 8a, b, and 10a, b) have been designed and synthesized through the combination of thiazole and pyrazoline moieties, starting from the key building blocks pyrazoline carbothioamides (1a–b). These eighteen derivatives have been d...

Descripción completa

Detalles Bibliográficos
Autores principales: Fakhry, Mariam M., Mattar, Amr A., Alsulaimany, Marwa, Al-Olayan, Ebtesam M., Al-Rashood, Sara T., Abdel-Aziz, Hatem A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10647861/
https://www.ncbi.nlm.nih.gov/pubmed/37959874
http://dx.doi.org/10.3390/molecules28217455
_version_ 1785135205851332608
author Fakhry, Mariam M.
Mattar, Amr A.
Alsulaimany, Marwa
Al-Olayan, Ebtesam M.
Al-Rashood, Sara T.
Abdel-Aziz, Hatem A.
author_facet Fakhry, Mariam M.
Mattar, Amr A.
Alsulaimany, Marwa
Al-Olayan, Ebtesam M.
Al-Rashood, Sara T.
Abdel-Aziz, Hatem A.
author_sort Fakhry, Mariam M.
collection PubMed
description A new series of thiazolyl-pyrazoline derivatives (4a–d, 5a–d 6a, b, 7a–d, 8a, b, and 10a, b) have been designed and synthesized through the combination of thiazole and pyrazoline moieties, starting from the key building blocks pyrazoline carbothioamides (1a–b). These eighteen derivatives have been designed as anticipated EGFR/HER2 dual inhibitors. The efficacy of the developed compounds in inhibiting cell proliferation was assessed using the breast cancer MCF-7 cell line. Among the new synthesized thiazolyl-pyrazolines, compounds 6a, 6b, 10a, and 10b displayed potent anticancer activity toward MCF-7 with IC(50) = 4.08, 5.64, 3.37, and 3.54 µM, respectively, when compared with lapatinib (IC(50) = 5.88 µM). In addition, enzymatic assays were also run for the most cytotoxic compounds (6a and 6b) toward EGFR and HER2 to demonstrate their dual inhibitory activity. They revealed promising inhibition potency against EGFR with IC(50) = 0.024, and 0.005 µM, respectively, whereas their IC(50) = 0.047 and 0.022 µM toward HER2, respectively, compared with lapatinib (IC(50) = 0.007 and 0.018 µM). Both compounds 6a and 10a induced apoptosis by arresting the cell cycle of the MCF-7 cell line at the G1 and G1/S phases, respectively. Molecular modeling studies for the promising candidates 6a and 10a showed that they formed the essential binding with the crucial amino acids for EGFR and HER2 inhibition, supporting the in vitro assay results. Furthermore, ADMET study predictions were carried out for the compounds in the study.
format Online
Article
Text
id pubmed-10647861
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-106478612023-11-06 New Thiazolyl-Pyrazoline Derivatives as Potential Dual EGFR/HER2 Inhibitors: Design, Synthesis, Anticancer Activity Evaluation and In Silico Study Fakhry, Mariam M. Mattar, Amr A. Alsulaimany, Marwa Al-Olayan, Ebtesam M. Al-Rashood, Sara T. Abdel-Aziz, Hatem A. Molecules Article A new series of thiazolyl-pyrazoline derivatives (4a–d, 5a–d 6a, b, 7a–d, 8a, b, and 10a, b) have been designed and synthesized through the combination of thiazole and pyrazoline moieties, starting from the key building blocks pyrazoline carbothioamides (1a–b). These eighteen derivatives have been designed as anticipated EGFR/HER2 dual inhibitors. The efficacy of the developed compounds in inhibiting cell proliferation was assessed using the breast cancer MCF-7 cell line. Among the new synthesized thiazolyl-pyrazolines, compounds 6a, 6b, 10a, and 10b displayed potent anticancer activity toward MCF-7 with IC(50) = 4.08, 5.64, 3.37, and 3.54 µM, respectively, when compared with lapatinib (IC(50) = 5.88 µM). In addition, enzymatic assays were also run for the most cytotoxic compounds (6a and 6b) toward EGFR and HER2 to demonstrate their dual inhibitory activity. They revealed promising inhibition potency against EGFR with IC(50) = 0.024, and 0.005 µM, respectively, whereas their IC(50) = 0.047 and 0.022 µM toward HER2, respectively, compared with lapatinib (IC(50) = 0.007 and 0.018 µM). Both compounds 6a and 10a induced apoptosis by arresting the cell cycle of the MCF-7 cell line at the G1 and G1/S phases, respectively. Molecular modeling studies for the promising candidates 6a and 10a showed that they formed the essential binding with the crucial amino acids for EGFR and HER2 inhibition, supporting the in vitro assay results. Furthermore, ADMET study predictions were carried out for the compounds in the study. MDPI 2023-11-06 /pmc/articles/PMC10647861/ /pubmed/37959874 http://dx.doi.org/10.3390/molecules28217455 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Fakhry, Mariam M.
Mattar, Amr A.
Alsulaimany, Marwa
Al-Olayan, Ebtesam M.
Al-Rashood, Sara T.
Abdel-Aziz, Hatem A.
New Thiazolyl-Pyrazoline Derivatives as Potential Dual EGFR/HER2 Inhibitors: Design, Synthesis, Anticancer Activity Evaluation and In Silico Study
title New Thiazolyl-Pyrazoline Derivatives as Potential Dual EGFR/HER2 Inhibitors: Design, Synthesis, Anticancer Activity Evaluation and In Silico Study
title_full New Thiazolyl-Pyrazoline Derivatives as Potential Dual EGFR/HER2 Inhibitors: Design, Synthesis, Anticancer Activity Evaluation and In Silico Study
title_fullStr New Thiazolyl-Pyrazoline Derivatives as Potential Dual EGFR/HER2 Inhibitors: Design, Synthesis, Anticancer Activity Evaluation and In Silico Study
title_full_unstemmed New Thiazolyl-Pyrazoline Derivatives as Potential Dual EGFR/HER2 Inhibitors: Design, Synthesis, Anticancer Activity Evaluation and In Silico Study
title_short New Thiazolyl-Pyrazoline Derivatives as Potential Dual EGFR/HER2 Inhibitors: Design, Synthesis, Anticancer Activity Evaluation and In Silico Study
title_sort new thiazolyl-pyrazoline derivatives as potential dual egfr/her2 inhibitors: design, synthesis, anticancer activity evaluation and in silico study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10647861/
https://www.ncbi.nlm.nih.gov/pubmed/37959874
http://dx.doi.org/10.3390/molecules28217455
work_keys_str_mv AT fakhrymariamm newthiazolylpyrazolinederivativesaspotentialdualegfrher2inhibitorsdesignsynthesisanticanceractivityevaluationandinsilicostudy
AT mattaramra newthiazolylpyrazolinederivativesaspotentialdualegfrher2inhibitorsdesignsynthesisanticanceractivityevaluationandinsilicostudy
AT alsulaimanymarwa newthiazolylpyrazolinederivativesaspotentialdualegfrher2inhibitorsdesignsynthesisanticanceractivityevaluationandinsilicostudy
AT alolayanebtesamm newthiazolylpyrazolinederivativesaspotentialdualegfrher2inhibitorsdesignsynthesisanticanceractivityevaluationandinsilicostudy
AT alrashoodsarat newthiazolylpyrazolinederivativesaspotentialdualegfrher2inhibitorsdesignsynthesisanticanceractivityevaluationandinsilicostudy
AT abdelazizhatema newthiazolylpyrazolinederivativesaspotentialdualegfrher2inhibitorsdesignsynthesisanticanceractivityevaluationandinsilicostudy